| Source: |
| Type: |
| DNA methylation, an epigenetic modification, regulates gene transcription and maintains genome stability. DNA methyltransferase (DNMT) inhibitors can activate silenced genes at low doses and cause cytotoxicity at high doses. High expression levels of DNMTs, particularly DNMT1 and DNMT3A, are often associated with poor prognosis in several cancers. This is due to their role in promoting tumor growth, metastasis, and resistance to therapies. |
| Cervical Cancer |
| 3435- | aLinA, | Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | SiHa | - | in-vitro, | Cerv, | C33A |
| 3233- | EGCG, | Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways |
| - | in-vitro, | Cerv, | HeLa |
| 3235- | EGCG, | (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells |
| - | in-vivo, | Cerv, | HeLa |
| 2927- | LT, | Luteolin Causes 5′CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells |
| - | in-vitro, | Cerv, | HeLa |
| 3359- | QC, | Quercetin modifies 5′CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells |
| - | in-vitro, | Cerv, | HeLa |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:29 Cells:% prod#:% Target#:469 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid